Enhanced survival of rifampin- and streptomycin-resistant Escherichia coli inside macrophages

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 7, 2016, Pages 4324-4332

  Durão, Paulo ^a   Gülereşi, Daniela ^a   Proença, João ^a   Gordo, Isabel ^a  

^a INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; RIFAMPICIN; STREPTOMYCIN; ANTIINFECTIVE AGENT;

ALLELE; ANIMAL CELL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL SURVIVAL; COCULTURE; COMPETITIVE ABILITY; EPISTASIS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI K 12; GENE EXPRESSION; GENE MUTATION; GENOTYPE; MACROPHAGE; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STREPTOMYCIN RESISTANT ESCHERICHIA COLI; ANIMAL; DRUG EFFECTS; GENETICS; MICROBIOLOGY; MOUSE; MULTIDRUG RESISTANCE; RAW 264.7 CELL LINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; MACROPHAGES; MICE; RAW 264.7 CELLS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIFAMPIN; STREPTOMYCIN;

EID: 84976877620     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00624-16     Document Type: Article

References (55)

1. Palumbi SR. 2001. Humans as the world's greatest evolutionary force. Science 293:1786-1790. http://dx.doi.org/10.1126/science.293.5536.1786.
2. Trindade S, Sousa A, Xavier KB, Dionisio F, Ferreira MG, Gordo I. 2009. Positive epistasis drives the acquisition of multidrug resistance. PLoS Genet 5:e1000578. http://dx.doi.org/10.1371/journal.pgen.1000578.
3. MacLean RC, Buckling A. 2009. The distribution of fitness effects of beneficial mutations in Pseudomonas aeruginosa . PLoS Genet 5:e1000406. http://dx.doi.org/10.1371/journal.pgen.1000406.
4. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. 2006. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312:1944-946. http://dx.doi.org/10.1126/science.1124410.
5. Andersson DI, Levin BR. 1999. The biological cost of antibiotic resistance. Curr Opin Microbiol 2:489-493. http://dx.doi.org/10.1016/S1369-5274(99)00005-3.
6. Lenski RE. 1998. Bacterial evolution and the cost of antibiotic resistance. Int Microbiol 1:265-270.
7. Andersson DI, Hughes D. 2010. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 8:260-271. http://dx.doi.org/10.1038/nrmicro2319.
8. Björkman J, Nagaev I, Berg OG, Hughes D, Andersson DI. 2000. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287:1479-1482. http://dx.doi.org/10.1126/science.287.5457.1479.
9. Chait R, Craney A, Kishony R. 2007. Antibiotic interactions that select against resistance. Nature 446:668-671. http://dx.doi.org/10.1038/nature05685.
10. Koch A, Mizrahi V, Warner DF. 2014. The impact of drug resistance on Mycobacterium tuberculosis physiology: what can we learn from rifampicin? Emerg Microbes Infect 3:e17. http://dx.doi.org/10.1038/emi.2014.17.
11. Borrell S, Teo Y, Giardina F, Streicher EM, Klopper M, Feldmann J, Müller B, Victor TC, Gagneux S. 2013. Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis. Evol Med Public Health 1:65-74. http://dx.doi.org/10.1093/emph/eot003.
12. Hall AR, MacLean RC. 2011. Epistasis buffers the fitness effects of rifampicin resistance mutations in Pseudomonas aeruginosa . Evolution 65: 2370-2379. http://dx.doi.org/10.1111/j.1558-5646.2011.01302.x.
13. Durão P, Trindade S, Sousa A, Gordo I. 2015. Multiple resistance at no cost: rifampicin and streptomycin a dangerous liaison in the spread of antibiotic resistance. Mol Biol. Evol 32:2675-2680. http://dx.doi.org/10.1093/molbev/msv143.
14. Tenaillon O, Skurnik D, Picard B, Denamur E. 2010. The population genetics of commensal Escherichia coli . Nat Rev Microbiol 8:207-217. http://dx.doi.org/10.1038/nrmicro2298.
15. Crossman LC, Chaudhuri RR, Beatson SA, Wells TJ, Desvaux M, Cunningham AF, Petty NK, Mahon V, Brinkley C, Hobman JL, Savarino SJ, Turner SM, Pallen MJ, Penn CW, Parkhill J, Turner AK, Johnson TJ, Thomson NR, Smith SGJ, Henderson IR. 2010. A commensal gone bad: complete genome sequence of the prototypical enterotoxigenic Escherichia coli strain H10407. J Bacteriol 192:5822-5831. http://dx.doi.org/10.1128/JB.00710-10.
16. Denamur E, Picard B, Tenaillon O. 2010. Population genetics of pathogenic Escherichia coli, p 269-289. In Robinson DA, Feil EF (ed), Bacterial population genetics in infectious disease. John Wiley & Sons, Inc, Hoboken, NJ.
17. Sharma U, Schwan WR, Agger WA. 2011. Escherichia coli pyomyositis in an immunocompromised host. WMJ 110:182-184.
18. Janny S, Bert F, Dondero F, Chanoine MH, Belghiti J, Mantz J, Paugam-Burtz C. 2013. Fatal Escherichia coli skin and soft tissue infections in liver transplant recipients: report of three cases. Transpl Infect Dis 15:E49-E53. http://dx.doi.org/10.1111/tid.12046.
19. Sanz-García M, Fernández-Cruz A, Rodríguez-Créixems M, Cercenado E, Marin M, Muñoz P, Bouza E. 2009. Recurrent Escherichia coli bloodstream infections: epidemiology and risk factors. Medicine 88:77-82. http://dx.doi.org/10.1097/MD.0b013e31819dd0cf.
20. Miskinyte M, Gordo I. 2013. Increased survival of antibiotic-resistant Escherichia coli inside macrophages. Antimicrob Agents Chemother 57: 189-195. http://dx.doi.org/10.1128/AAC.01632-12.
21. Trindade S, Sousa A, Gordo I. 2012. Antibiotic resistance and stress in the light of Fisher's model. Evolution 66:3815-3824. http://dx.doi.org/10.1111/j.1558-5646.2012.01722.x.
22. MacLean RC, Perron GG, Gardner A. 2010. Diminishing returns from beneficial mutations and pervasive epistasis shape the fitness landscape for rifampicin resistance in Pseudomonas aeruginosa . Genetics 186:1345-1354. http://dx.doi.org/10.1534/genetics.110.123083.
23. Ward H, Perron GG, Maclean RC. 2009. The cost of multiple drug resistance in Pseudomonas aeruginosa . J Evol Biol 22:997-1003. http://dx.doi.org/10.1111/j.1420-9101.2009.01712.x.
24. Thomason LC, Costantino N, Court DL. 2007. Escherichia coli genome manipulation by P1 transduction. Curr Protoc Mol Biol Chapter 1:Unit 1.17. http://dx.doi.org/10.1002/0471142727.mb0117s79.
25. Vogel J, Bartels V, Tang TH, Churakov G, Slagter-Jäger JG, Hüttenhofer A, Wagner EG. 2003. RNomics in Escherichia coli detects new sRNA species and indicates parallel transcriptional output in bacteria. Nucleic Acids Res 31:6435. http://dx.doi.org/10.1093/nar/gkg867.
26. Hamrick TS, Havell EA, Horton JR, Orndorff PE. 2000. Host and bacterial factors involved in the innate ability of mouse macrophages to eliminate internalized unopsonized Escherichia coli . Infect Immun 68: 125-132. http://dx.doi.org/10.1128/IAI.68.1.125-132.2000.
27. Björkbacka H, Fitzgerald KA, Huet F, Li X, Gregory JA, Lee MA, Ordija CM, Dowley NE, Golenbock DT, Freeman MW. 2004. The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades. Physiol Genomics 19:319-330. http://dx.doi.org/10.1152/physiolgenomics.00128.2004.
28. Miskinyte M, Sousa A, Ramiro RS, Moura de Sousa JA, Kotlinowski J, Caramalho I, Magalhães S, Soares MP, Gordo I. 2013. The genetic basis of Escherichia coli pathoadaptation to macrophages. PLoS Pathog 9:e1003802. http://dx.doi.org/10.1371/journal.ppat.1003802.
29. Elena SF, Lenski RE. 2003. Evolution experiments with microorganisms: the dynamics and genetic bases of adaptation. Nat Rev Genet 4:457-469. http://dx.doi.org/10.1038/nrm1129, 10.1038/ni916, 10.1038/nrg1088.
30. Ferenci T. 2005. Maintaining a healthy SPANC balance through regulatory and mutational adaptation. Mol Microbiol 57:1-8. http://dx.doi.org/10.1111/j.1365-2958.2005.04649.x.
31. De Paepe M, Gaboriau-Routhiau V, Rainteau D, Rakotobe S, Taddei F, Cerf-Bensussan N. 2011. Trade-off between bile resistance and nutritional competence drives Escherichia coli diversification in the mouse gut. PLoS Genet 7:e1002107. http://dx.doi.org/10.1371/journal.pgen.1002107.
32. Barreto A, Guimaraes B, Radhouani H, Araujo C, Goncalves A, Gaspar E, Rodrigues J, Igrejas G, Poeta P. 2009. Detection of antibiotic resistant Escherichia coli and Enterococcus spp. in stool of healthy growing children in Portugal. J Basic Microbiol 49:503-512. http://dx.doi.org/10.1002/jobm.200900124.
33. Hong S, Choi YH, Choo YA, Choi Y, Choi SY, Kim DW, Lee BK, Park MS. 2010. Genetic characterization of atypical Shigella flexneri isolated in Korea. J Microbiol Biotechnol 20:1457-1462. http://dx.doi.org/10.4014/jmb.1005.05019.
34. Rahmani F, Fooladi AA, Marashi SM, Nourani MR. 2012. Drug resistance in Vibrio cholerae strains isolated from clinical specimens. Acta Microbiol Immunol Hung 59:77-84. http://dx.doi.org/10.1556/AMicr.59.2012.1.8.
35. Tseng JT, Bryan LE, Van Den Elzen HM. 1972. Mechanisms and spectrum of streptomycin resistance in a natural population of Pseudomonas aeruginosa . Antimicrob Agents Chemother 2:136-141. http://dx.doi.org/10.1128/AAC.2.3.136.
36. Crofton J, Mitchison DA. 1948. Streptomycin resistance in pulmonary tuberculosis. Br Med J 2:1009-1015. http://dx.doi.org/10.1136/bmj.2.4588.1009.
37. Cavusoglu C, Turhan A, Akinci P, Soyler I. 2006. Evaluation of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis isolates. J Clin Microbiol 44: 2338-2342. http://dx.doi.org/10.1128/JCM.00425-06.
38. Kapur V, Li LL, Iordanescu S, Hamrick MR, Wanger A, Kreiswirth BN, Musser JM. 1994. Characterization by automated DNA sequencing 315 of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol 32:1095-1098.
39. Yue J, Shi W, Xie J, Li Y, Zeng E, Wang H. 2003. Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates 385 from China. J Clin Microbiol 41:2209-2212. http://dx.doi.org/10.1128/JCM.41.5.2209-2212.2003.
40. Roux D, Danilchanka O, Guillard T, Cattoir V, Aschard H, Fu Y, Angoulvant F, Messika J, Ricard J, Mekalanos JJ, Lory S, Pier GB, Skurnik D. 2015. Fitness cost of antibiotic susceptibility during bacterial infection. Sci Transl Med 7:297ra114. http://dx.doi.org/10.1126/scitranslmed.aab1621.
41. Skurnik D, Roux D, Cattoir V, Danilchanka O, Lu X, Yoder-Himes DR, Han K, Guillard T, Jiang D, Gaultier C, Guerin F, Aschard H, Leclercq R, Mekalanos JJ, Lory S, Pier GB. 2013. Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa revealed through high-throughput sequencing. Proc Natl Acad Sci U S A 110: 20747-20752. http://dx.doi.org/10.1073/pnas.1221552110.
42. Koch G, Yepes A, Foerstner KU, Wermser C, Stengel ST, Modamio J, Ohlsen K, Foster KR, Lopez D. 2014. Evolution of resistance to a last-resort antibiotic in Staphylococcus aureus via bacterial competition. Cell 158:1060-1071. http://dx.doi.org/10.1016/j.cell.2014.06.046.
43. Sander LE, Davis MJ, Boekschoten MV, Amsen D, Dascher CC, Ryffel B, Swanson JA, Müller M, Blander JM. 2011. Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. Nature 474: 385. http://dx.doi.org/10.1038/nature10072.
44. Rathinam VA, Vanaja SK, Waggoner L, Sokolovska A, Becker C, Stuart LM, Leong JM, Fitzgerald KA. 2012. TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria. Cell 150:606. http://dx.doi.org/10.1016/j.cell.2012.07.007.
45. Yen H, Sugimoto N, Tobe T. 2015. Enteropathogenic Escherichia coli uses NleA to inhibit NLRP3 inflammasome activation. PLoS Pathog 11: e1005121. http://dx.doi.org/10.1371/journal.ppat.1005121.
46. Pichlmair A, Lassnig C, Eberle1 Górna CMW, Baumann CL, Burkard TR, Bürckstümmer T, Stefanovic A, Krieger S, Bennett KL, Rülicke T, Weber F, Colinge J, Müller M, Superti-Furga G. 2011. IFIT1 is an antiviral protein that recognizes 5′-triphosphate RNA. Nat Immunol 12: 624-630. http://dx.doi.org/10.1038/ni.2048.
47. Malireddi RK, Kanneganti TD. 2013. Role of type I interferons in inflammasome activation, cell death, and disease during microbial infection. Front Cell Infect Microbiol 3:77. http://dx.doi.org/10.3389/fcimb.2013.00077.
48. Decker T, Muller M, Stockinger S. 2005. The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol 5:675. http://dx.doi.org/10.1038/nri1684.
49. Dinarello CA. 2001. IL-1α, p 307-318. In Durum SK, Oppenheim JJ, Feldmann M (ed), Cytokine reference: a compendium of cytokines and other mediators of host defense. Academic Press, Inc., Boston, MA.
50. Saraiva M, O'Garra A. 2010. The regulation of IL-10 production by immune cells. Nat Rev Immunol 10:170-181. http://dx.doi.org/10.1038/nri2711.
51. Mavromatis CH, Bokil NJ, Totsika M, Kakkanat A, Schaale K, Cannistraci CV, Ryu T, Beatson SA, Ulett GC, Schembri MA, Sweet MJ, Ravasi T. 2015. The cotranscriptome of uropathogenic Escherichia coli-infected mouse macrophages reveals new insights into host-pathogen interactions. Cell Microbiol 17:730. http://dx.doi.org/10.1111/cmi.12397.
52. Zaher HS, Green R. 2010. Hyperaccurate and error-prone ribosomes exploit distinct mechanisms during tRNA selection. Mol Cell 39:110-120. http://dx.doi.org/10.1016/j.molcel.2010.06.009.
53. Bilgin N, Claesens F, Pahverk H, Ehrenberg M. 1992. Kinetic properties of Escherichia coli ribosomes with altered forms of S12. J Mol Biol 224: 1011-1027. http://dx.doi.org/10.1016/0022-2836(92)90466-W.
54. Ballesteros M, Fredriksson A, Henriksson J, Nystrom T. 2001. Bacterial senescence: protein oxidation in nonproliferating cells is dictated by the accuracy of the ribosomes. EMBO J 20:5280-5289. http://dx.doi.org/10.1093/emboj/20.18.5280.
55. Pieters J, Gatfield J. 2002. Hijacking the host: survival of pathogenic mycobacteria inside macrophages. Trends Microbiol 10:142-146. http://dx.doi.org/10.1016/S0966-842X(02)02305-3.